Haemonetics Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 82.22.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Haemonetics Corp is 7.52, ranking 68 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 338.97M, representing a year-over-year decrease of 2.75%, while its net profit experienced a year-over-year decrease of 19.33%.
Key Metrics
The current valuation score of Haemonetics Corp is 7.71, ranking 65 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 15.46, which is 211.63% below the recent high of 48.18 and 7.20% above the recent low of 14.35.
The current earnings forecast score of Haemonetics Corp is 7.82, ranking 116 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 88.00, with a high of 108.00 and a low of 62.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Haemonetics Corp is 7.26, ranking 56 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 61.98 and the support level at 50.80, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Haemonetics Corp is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 126.77%, representing a quarter-over-quarter increase of 14.38%. The largest institutional shareholder is Steven Cohen, holding a total of 853.38K shares, representing 1.84% of shares outstanding, with 109.56% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Haemonetics Corp is 6.94, ranking 48 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
